Sequenced from human survivors of COVID-19 (SARS-CoV-2). These are made recombinantly in HEK293 cells. The spike RBD is expressed on the surface of SARS-CoV-2.
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added.
Formulierung:
Liquid
Anwendungsbeschreibung:
Application Notes: ELISA, N, IHC (Other applications as reported in literature)
SARS-CoV-2 Spike RBD Antibody (clone 2165) IHC Data using infected cell pellets.
Coating: Purified Recombinant SARS-CoV-2 Spike RBD, concentration of 1 ul/well, 100 ul/well overnight 2-8 °C. Detection: Anti-SARS-CoV-2 RBD (Clone 2165) conjugated to HRP was serially diluted starting at 25 ng/ml down to 0.23 ng/ml, 100 ul/well for 1 hour at 37 °C. Substrate: TMB, 100 ul/well for 15 min, at room temperature followed by 450 nm stop solution, 50ul/well.
Anti-SARS-CoV-2 Antibody to the Recepter Binding Domain (RBD) (Clone 2165). Antibody binds to RBD and blocks binding to the ACE2 receptor on coated plates using COVID-19 ImmunoRank Neurilization MICRO-ELISA Assay.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
